Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
Represents Fourth FDA Grant for Simcyp MechDermA Model for Virtual Bioequivalence PRINCETON, N.J.— September 20, 2021. Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S. Food and Drug Administration (FDA) to verify and expand biosimulation models for assessing virtual bioequivalence (VBE) to help enable … Continued